Literature DB >> 12890715

Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin.

Stefano Fiorucci1, Eleonora Distrutti, Andrea Mencarelli, Antonio Morelli, Stefan A Laufor, Giuseppe Cirino, John L Wallace.   

Abstract

(1) Unlike other nonsteroidal anti-inflammatory drugs that inhibit formation of cyclooxygenase (COX)-dependent eicosanoids, acetylation of COX-2 by aspirin switches eicosanoid biosynthesis from prostaglandin E(2) (PGE(2)) to 15-epi-lipoxin A(4) (15-epi-LXA(4) or aspirin-triggered lipoxin, ATL). ATL formation by activated leukocytes (PMN) requires the intervention of 5-lipoxygenase (5-LOX), an enzyme that is involved in leukotriene B(4) (LTB(4)) formation. (2) In the present study, we have examined the role of acetylated COX-2 and 5-LOX in modulating antiadhesive effects of aspirin on adhesion of PMN to endotoxin (LPS)-primed human umbilical endothelial cells (HUVEC). (3) Treating PMN/HUVEC cocultures with aspirin resulted in a concentration-dependent inhibition of cell-to-cell adhesion induced by LPS. Treating HUVEC with selective COX-2 inhibitors, celecoxib and rofecoxib, caused an approximately 70% reversion of antiadhesive effect of aspirin. In contrast, inhibition of neutrophil's 5-LOX pathway with 1 micro M ZD2138, a selective 5-LOX inhibitor, 1 micro M BAY-X-1005, a FLAP inhibitor, or 100 micro M licofelone, a dual COX/5-LOX inhibitor, did not affect antiadhesive properties of aspirin. (4) Exposure to celecoxib (100 micro M) or rofecoxib (10 micro M) completely suppressed ATL formation caused by aspirin without affecting LTB(4) levels. ZD2138, licofelone and BAY-X-1005 inhibited ATL formation as well as LTB(4) generation. (5) Treatment with LXA(4) reduced PMN adhesion to HUVEC and counteracted the proadhesive effect of celecoxib. In contrast, exposure to Boc-1, an LXA(4) antagonist, counteracts the antiadhesive activities of aspirin. Exposure to U75302, an LTB(4) receptor antagonist, enhances the antiadesive effect of aspirin. (6) Reversal of antiadhesive activities of aspirin by celecoxib was associated with increased expression of LFA-1 on PMN and E-selectin on HUVEC. Addition of LXA(4), ZD2138 and U75302 inhibited these changes. (7) The present results support the notion that inhibition of ATL formation is mechanistically linked to the reversal of the antiadhesive activity of aspirin caused by selective COX-1 inhibitors and suggests that the LTB(4)/ATL balance modulates pro- and antiadhesive activity of nonsteroidal anti-inflammatory drugs at the leukocyte-endothelial cell interface.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890715      PMCID: PMC1573955          DOI: 10.1038/sj.bjp.0705356

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

Review 1.  Leukocyte-endothelial adhesion molecules.

Authors:  T M Carlos; J M Harlan
Journal:  Blood       Date:  1994-10-01       Impact factor: 22.113

2.  Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs.

Authors:  J A Mancini; P J Vickers; G P O'Neill; C Boily; J P Falgueyret; D Riendeau
Journal:  Mol Pharmacol       Date:  1997-01       Impact factor: 4.436

Review 3.  Aspirin as an antiplatelet drug.

Authors:  C Patrono
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

4.  BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.

Authors:  R Müller-Peddinghaus; C Kohlsdorfer; P Theisen-Popp; R Fruchtmann; E Perzborn; B Beckermann; K Bühner; H J Ahr; K H Mohrs
Journal:  J Pharmacol Exp Ther       Date:  1993-10       Impact factor: 4.030

5.  Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration.

Authors:  J W Pierce; M A Read; H Ding; F W Luscinskas; T Collins
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

6.  Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction.

Authors:  S Fiore; C N Serhan
Journal:  Biochemistry       Date:  1995-12-26       Impact factor: 3.162

7.  (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase.

Authors:  S A Laufer; J Augustin; G Dannhardt; W Kiefer
Journal:  J Med Chem       Date:  1994-06-10       Impact factor: 7.446

8.  Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.

Authors:  W G Smith; A F Shaffer; J L Currie; J M Thompson; S Kim; T Rao; P C Isakson
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

9.  Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.

Authors:  J Clària; C N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

10.  Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors.

Authors:  T Takano; S Fiore; J F Maddox; H R Brady; N A Petasis; C N Serhan
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

View more
  14 in total

1.  Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites.

Authors:  Mireille Basselin; Epolia Ramadan; Mei Chen; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2010-10-28       Impact factor: 3.996

Review 2.  Resolution of inflammation in periodontitis.

Authors:  Alpdogan Kantarci; Thomas E Van Dyke
Journal:  J Periodontol       Date:  2005-11       Impact factor: 6.993

3.  Aspirin in the prevention of preeclampsia: the conundrum of how, who and when.

Authors:  Renuka Shanmugalingam; Annemarie Hennessy; Angela Makris
Journal:  J Hum Hypertens       Date:  2018-09-19       Impact factor: 3.012

4.  Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium.

Authors:  Sreedevi Chinthamani; Olutayo Odusanwo; Nandini Mondal; Joel Nelson; Sriram Neelamegham; Olga J Baker
Journal:  Am J Physiol Cell Physiol       Date:  2011-12-28       Impact factor: 4.249

5.  Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma.

Authors:  A M Gil-Villa; L V Norling; C N Serhan; D Cordero; M Rojas; A Cadavid
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2012-09-10       Impact factor: 4.006

Review 6.  A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution.

Authors:  Charles N Serhan
Journal:  Histochem Cell Biol       Date:  2004-08-21       Impact factor: 4.304

7.  Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety.

Authors:  A E Chávez-Piña; L Vong; W McKnight; M Dicay; R C O Zanardo; M I Ortiz; G Castañeda-Hernández; J L Wallace
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

8.  15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation.

Authors:  Mark J Paul-Clark; Thong Van Cao; Niloufar Moradi-Bidhendi; Dianne Cooper; Derek W Gilroy
Journal:  J Exp Med       Date:  2004-07-05       Impact factor: 14.307

Review 9.  Function of Pro-Resolving Lipid Mediator Resolvin E1 in Type 2 Diabetes.

Authors:  Corneliu Sima; Bruce Paster; Thomas E Van Dyke
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

10.  Neutrophil activation status in stable coronary artery disease.

Authors:  Eva Särndahl; Ida Bergström; Veronika Patcha Brodin; Johnny Nijm; Helen Lundqvist Setterud; Lena Jonasson
Journal:  PLoS One       Date:  2007-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.